Astellas Pharma Inc. is a Japanese multinational pharmaceutical company headquartered in Tokyo. Formed in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, the company discovers, develops, manufactures, and markets prescription medicines worldwide. Its research focuses on areas such as oncology, urology, immunology, neuroscience, ophthalmology, and rare diseases, with growing activity in advanced modalities including cell and gene therapies.
For the broader chemicals and life sciences ecosystem, Astellas integrates small‑molecule and biologics R&D with process chemistry, formulation development, and CMC disciplines, operating cGMP manufacturing and quality systems across Japan, the Americas, Europe, and Asia. The company participates in global supply chains for active pharmaceutical ingredients and drug products, and advances technologies such as antibody–drug conjugates and gene therapy manufacturing through internal capabilities and partnerships. Its operations emphasize regulatory compliance, pharmacovigilance, and product quality across the development-to-commercialization lifecycle.
To provide comprehensive coverage, we aggregate data and news under the name Astellas, encompassing the following company names, divisions, and related entities:
Astellas.
This list encompasses current and former names, alternate names, and key divisions associated with Astellas, ensuring you can easily find all relevant information under a single, unified profile.